ClinicalTrials.gg
CompletedNCT02009878Updated May 16, 2016Results posted

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

A Phase 1/2 interventional study of tolvaptan in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 14 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-16.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Inappropriate ADH Syndrome · Otsuka Holdings Co., Ltd..

Started
2013
the only one that year
Phase 1/2
Only one
of the 10
Registered
5th of 10
by date

Among the 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd., this one is the only one that started in 2013, is the only one in phase 1/2, and was the 5th registered.

Inappropriate ADH Syndrome

41 studies on the registry are indexed under Inappropriate ADH Syndrome; 3 are open to participants now.

Browse Inappropriate ADH Syndrome studies →

Open to participants now

None of the 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd. is open now. The open studies under Inappropriate ADH Syndrome, anywhere →

Who these studies take

Of the 3 Inappropriate ADH Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Inappropriate ADH Syndrome by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

This is a study to evaluate how the body handles and metabolizes (PK) the various doses of the drug Tolvaptan, and what the effect (PD) of the various doses of Tolvaptan are on the content of "salt" in blood and urine

03

Conditions studied

  • Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Keywords

  • SIADH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects greater than or equal to 18 years of age or the age of legal consent.
  • Must have a less than or equal to 32.0 kg/m2.
  • Subjects must have a diagnosis of SIADH prior to randomization.
  • Persistent euvolemic hyponatremia, evidenced by 3 serum sodium assessments of between 120 and 133 mmol/L, inclusive drawn locally as follows: one during the screening period, a second at check-in on Day -1, a third on Day 0 (12-24 hours prior to dosing), which will serve as the baseline value for efficacy endpoints
  • Subjects with relatively intact renal function, ie, estimated using the CKD-EPI formula of greater than or equal to 60 mL/min/1.73m2.
  • Ability to provide written, prior to initiation of any trial related procedures, and ability, in the opinion of the PI, to comply with all the requirements of the trial.
  • Sexually active males who are practicing a highly effective method of during the trial and for 30 days after the last dose of trial medication or who will remain abstinent during the trial and for 30 days after the last dose, or sexually active females of who are practicing a highly effective method of birth control during the trial and for 30 days after the last dose of trial medication or who will remain abstinent during the trial and for 30 days after the last dose, or female subjects of nonchildbearing potential (surgically sterile or [1 year post menses]). If employing birth control, 1 of the following highly effective methods (failure rate \<1%) must be used: vasectomy, tubal ligation, intrauterine device containing hormone (Mirena), combined oral contraceptive, hormone implants or hormone injections.

Exclusion criteria

Exclusion Criteria:

  • Daily use of diuretics within 14 days prior to screening assessments or randomization or the requirement for constant diuretic use for any reason.
  • Clinically assessed hypovolemic state.
  • Inability to respond to thirst.
  • Subjects who cannot perceive thirst.
  • Subjects with anuria.
  • Urgent need to raise serum sodium acutely.
  • Urinary outflow obstruction unless the subject is, or can be, catheterized during the trial.
  • Severe hepatic impairment. Class C (score of 10 or greater).
  • Subjects who receive any medication given for the purpose of raising serum sodium while undergoing qualifying serum sodium assessments. Specifically: Hypertonic saline (including normal saline challenge) within 8 hours before each qualifying serum sodium screening assessment; Urea, lithium, demeclocycline, conivaptan, or tolvaptan within 4 days of each qualifying serum sodium screening assessment; Loop diuretics (eg. furosemide, bumetanide, torsemide) within 48 hours of each qualifying serum sodium screening assessment; Other treatment (including normal saline or oral sodium containing supplements) for the purpose of increasing serum sodium within 24 hours of each qualifying serum sodium screening assessment. Final determination will be made in consultation with the sponsor.
  • Subjects with medication induced SIADH who have not been on stable medication for 3 months.
  • inhibitors taken within 5 elimination half-lives or within 96 hours of dosing, which ever time is longer. Final determination will be made in consultation with the sponsor.
  • CYP3A4 inducers taken within 72 hours after 5 elimination half-lives (eg, rifampin, St. Johns Wort).
  • Chemotherapy agents given in the previous 7 days prior to dosing or within 5 elimination half-lives of the agent; whichever is longer.
  • abnormality in past medical history, or at the Screening physical examination, that in the investigator's or sponsor's opinion may place the subject at risk or interfere with outcome variables including absorption, distribution, metabolism, and excretion of drug. This includes, but is not limited to, history of or concurrent cardiac, hepatic, renal, neurologic, endocrine, GI, respiratory, hematologic, and immunologic disease.
  • History of drug and/or alcohol abuse within 6 months prior to Screening.
  • History of or current hepatitis or acquired immunodeficiency syndrome or carriers of , anti-, and/or antibodies.
  • History of any significant drug allergy.
  • A positive alcohol test and/or drug screen for substance of abuse at Screening or upon Check-in to the clinical site.
  • Subjects having taken an drug within 30 days preceding trial entry.
  • Any history of significant bleeding or hemorrhagic tendencies.
  • A history of difficulty in donating blood.
  • The donation of blood or plasma within 30 days prior to dosing.
  • Consumption of alcohol and/or food and beverages containing methylxanthines, pomelo fruit, grapefruit, grapefruit juice, Seville oranges, or Seville orange juice within 72 hours prior to dosing.
  • Exposure to any substances known to stimulate hepatic microsomal enzymes within 30 days prior to Screening (eg, occupational exposure to pesticides, organic solvents).
  • Has Screening liver function values > 3 x .
  • Has primary polydipsia.
  • Inability to take oral medications.
  • Subjects who have supine blood pressure, after resting for greater than or equal to 3 minutes, higher than 140/90 mmHg or lower than 100/50 mmHg. The sponsor may allow exceptions if they are not deemed clinically significant.
  • Subjects who have a supine pulse rate, after resting for greater than or equal to 3 minutes, outside the range of 40 to 90 bpm. The sponsor may allow exceptions significant.
  • History of serious mental disorders that, in the opinion of the investigator, would exclude the subject from participating in this trial.
  • Any subject who, in the opinion of the investigator, should not participate in the trial.
  • Subjects who are pregnant or breastfeeding. A negative serum pregnancy test must be confirmed prior to randomization for all female subjects of .
  • Subjects with Type 1 diabetes.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Other
    tolvaptan 3.75 mg

    tolvaptan 3.75 mg

    Drug: tolvaptan

  • Other
    tolvaptan 7.5 mg

    tolvaptan 7.5 mg

    Drug: tolvaptan

  • Other
    tolvaptan 15 mg

    tolvaptan 15 mg

    Drug: tolvaptan

Interventions

  • Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1

    Also known as: SAMSCA

06

What researchers measure

Primary outcomes

  1. Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.

    Maximal increase in serum sodium is summarized below by tolvaptan dose. Blood samples for determination of plasma concentrations of tolvaptan were collected predose and at 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose on Day 1 or at Early Termination (ET).

    Time frame: Baseline to Day 2

  2. Time of Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.

    Time of maximal increase in serum sodium is summarized in the table below by tolvaptan dose. Samples were taken on Day 0 (baseline) at the corresponding Day 1 predose time and 12 hours postdose time; and on Day 1 at predose and at 2, 4, 6, 8, 12, and 24 hours postdose.

    Time frame: Baseline to Day 2

Secondary outcomes

  1. Cmax (Maximum (Peak) Plasma Concentration) for Tolvaptan in Plasma.

    Blood samples for determination of plasma concentrations of tolvaptan were collected predose and 1, 2, 3, 4, 8, 12, 16, and 24 hours postdose on Day 1 or at ET. PK parameters in participants with SIADH following tolvaptan administration for three different doses are presented below.

    Time frame: Baseline to Day 2

  2. Tmax (Time to Maximum (Peak) Plasma Concentration) for Tolvaptan in Plasma

    Blood samples for determination of plasma concentrations of tolvaptan were collected predose and 1, 2, 3, 4, 8, 12, 16, and 24 hours postdose on Day 1 or at ET. PK parameters in participants with SIADH following tolvaptan administration for three different doses are presented below.

    Time frame: Baseline to Day 2

  3. AUC Infinity (Area Under the Concentration-time Curve From Time Zero to Infinity) for Tolvaptan in Plasma

    Blood samples for determination of plasma concentrations of tolvaptan were collected predose and 1, 2, 3, 4, 8, 12, 16, and 24 hours postdose on Day 1 or at ET. If an indwelling catheter was utilized, saline flushes were used. PK parameters in participants with SIADH following tolvaptan administration for three different doses are presented below.

    Time frame: Baseline to Day 2

  4. Change From Baseline in Serum Sodium Concentrations

    Samples were taken on Day 0 (baseline) at the corresponding Day 1 predose time and 12 hours postdose time; and on Day 1 at predose and at 2, 4, 6, 8, 12, and 24 hours postdose.

    Time frame: Baseline and Day 2

  5. Change From Baseline in Fluid Intake From 0-6 Hours, 0-12 Hours and 0-24 Hours

    Fluid intake was monitored on Day 0 (times relative to Day 1 dosing), and Day 1 at intervals of 0 to 6, 6 to 12, and 12 to 24 hours postdose. Fluid intake included fluid used for dosing (study medication and any concomitant medication); food items that included any significant amounts of water (e.g., Jello \[including Gelatin and Jelly dessert\] and soup) was added to the total fluid intake. Samples were taken on Day 0 (baseline) at the corresponding Day 1 predose time and 12 hours postdose time; and on Day 1 at predose and at 2, 4, 6, 8, 12, and 24 hours postdose.

    Time frame: Baseline and Day 2

  6. Change From Baseline in Fluid Balance (Fluid Intake Minus Urine Output) From 0-6 Hours, 0-12 Hours and 0-24 Hours.

    Fluid intake was monitored on Day 0 (times relative to Day 1 dosing), and Day 1 at intervals of 0 to 6, 6 to 12, and 12 to 24 hours postdose. Fluid intake included fluid used for dosing (study medication and any concomitant medication); food items that included any significant amounts of water (e.g., Jello \[including Gelatin and Jelly dessert\] and soup) was added to the total fluid intake. Urine was collected for baseline comparison on Day 0 for the 24 hour prior to Day 1 dosing at intervals of 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12 hours, and 12 to 24 hours relative to the Day 1 dosing time. Fluid balance was determined as fluid intake minus urine output.

    Time frame: 2 days

  7. Change From Baseline in Cumulative Urine Volume at 0-6 Hours, 0-12 Hours and 0-24 Hours.

    Urine was collected for baseline comparison on Day 0 for the 24 hour prior to Day 1 dosing at intervals of 0 to 2, 2 to 4, 4, to 6, 6, to 8, 8, to 12, and 12 to 24 hours relative to Day 1 dosing time. Urine was collected on Day 1 at intervals of 0 to 2,2 to 4, 4 to 6, 6 to 8, 8 to 12, and 12 to 24 hours postdose. For the start of the urine collection on Day 0, a window of 15 to 40 minutes prior to the assigned dosing time was acceptable, with the 0 to 24 hour collection period on Day 1 starting 24 hours after the start time on Day 0. Participants were asked to void immediately prior to the end of the collection interval. The volume of individual voids were measured and recorded prior to refrigerating. All voids in a collection interval were pooled at the end of the collection interval, at which time the volume was determined, recorded and an aliquot taken for osmolality, sodium, potassium, and creatinine assessments.

    Time frame: 2 days

07

Results

Posted May 16, 2016

Participant flow

The study was conducted in 30 participants (29 received treatment) at 14 trial sites in 7 countries.

Participant flow — Overall Study
MilestoneTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
Started10119
Completed10109
Not completed010
Withdrew: Participant met withdrawal criteria010

Outcome measures

PrimaryMaximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.

Maximal increase in serum sodium is summarized below by tolvaptan dose. Blood samples for determination of plasma concentrations of tolvaptan were collected predose and at 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours postdose on Day 1 or at Early Termination (ET).

Time frame:
Baseline to Day 2
Reported as:
Mean · mmol/L
Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.
mmol/LTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.3.6 ± 3.35.3 ± 2.57.9 ± 5.3
SecondaryCmax (Maximum (Peak) Plasma Concentration) for Tolvaptan in Plasma.

Blood samples for determination of plasma concentrations of tolvaptan were collected predose and 1, 2, 3, 4, 8, 12, 16, and 24 hours postdose on Day 1 or at ET. PK parameters in participants with SIADH following tolvaptan administration for three different doses are presented below.

Time frame:
Baseline to Day 2
Reported as:
Mean · ng/mL
Cmax (Maximum (Peak) Plasma Concentration) for Tolvaptan in Plasma.
ng/mLTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
Cmax (Maximum (Peak) Plasma Concentration) for Tolvaptan in Plasma.37.7 ± 12.6107 ± 48.9157 ± 68.1
SecondaryTmax (Time to Maximum (Peak) Plasma Concentration) for Tolvaptan in Plasma

Blood samples for determination of plasma concentrations of tolvaptan were collected predose and 1, 2, 3, 4, 8, 12, 16, and 24 hours postdose on Day 1 or at ET. PK parameters in participants with SIADH following tolvaptan administration for three different doses are presented below.

Time frame:
Baseline to Day 2
Reported as:
Median · hours
Tmax (Time to Maximum (Peak) Plasma Concentration) for Tolvaptan in Plasma
hoursTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
Tmax (Time to Maximum (Peak) Plasma Concentration) for Tolvaptan in Plasma1.50 (0.95 to 4.00)2.00 (1.00 to 4.00)2.00 (0.97 to 3.00)
SecondaryAUC Infinity (Area Under the Concentration-time Curve From Time Zero to Infinity) for Tolvaptan in Plasma

Blood samples for determination of plasma concentrations of tolvaptan were collected predose and 1, 2, 3, 4, 8, 12, 16, and 24 hours postdose on Day 1 or at ET. If an indwelling catheter was utilized, saline flushes were used. PK parameters in participants with SIADH following tolvaptan administration for three different doses are presented below.

Time frame:
Baseline to Day 2
Reported as:
Mean · ng·h/mL
AUC Infinity (Area Under the Concentration-time Curve From Time Zero to Infinity) for Tolvaptan in Plasma
ng·h/mLTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
AUC Infinity (Area Under the Concentration-time Curve From Time Zero to Infinity) for Tolvaptan in Plasma244 ± 90.7655 ± 3731000 ± 361
SecondaryChange From Baseline in Serum Sodium Concentrations

Samples were taken on Day 0 (baseline) at the corresponding Day 1 predose time and 12 hours postdose time; and on Day 1 at predose and at 2, 4, 6, 8, 12, and 24 hours postdose.

Time frame:
Baseline and Day 2
Reported as:
Mean · mmol/L
Change From Baseline in Serum Sodium Concentrations
mmol/LTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
(Day 0) 12 hour (N= 10, 9, 9)-2.5 ± 1.3-2.3 ± 3.0-2.6 ± 2.2
(Day 1) 2 hour (N= 10, 10, 8)-2.0 ± 4.42.4 ± 1.31.7 ± 1.8
(Day 1) 4 hour (N= 10, 10, 8)-1.7 ± 4.73.5 ± 3.03.0 ± 2.3
(Day 1) 6 hour (N= 10, 10, 8)-0.1 ± 4.73.1 ± 3.15.3 ± 4.2
(Day 1) 8 hour (N= 10, 10, 8)0.0 ± 4.83.2 ± 1.95.4 ± 4.6
(Day 1) 12 hour (N= 9, 10, 9)-0.6 ± 4.53.6 ± 1.85.9 ± 4.7
(Day 1) 24 hour (N= 10, 10, 9)2.9 ± 3.84.6 ± 1.97.4 ± 4.8
PrimaryTime of Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.

Time of maximal increase in serum sodium is summarized in the table below by tolvaptan dose. Samples were taken on Day 0 (baseline) at the corresponding Day 1 predose time and 12 hours postdose time; and on Day 1 at predose and at 2, 4, 6, 8, 12, and 24 hours postdose.

Time frame:
Baseline to Day 2
Reported as:
Median · hours
Time of Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.
hoursTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
Time of Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration.24.13 (2.03 to 24.25)6.38 (2.05 to 24.28)24.02 (6.25 to 24.30)
SecondaryChange From Baseline in Fluid Intake From 0-6 Hours, 0-12 Hours and 0-24 Hours

Fluid intake was monitored on Day 0 (times relative to Day 1 dosing), and Day 1 at intervals of 0 to 6, 6 to 12, and 12 to 24 hours postdose. Fluid intake included fluid used for dosing (study medication and any concomitant medication); food items that included any significant amounts of water (e.g., Jello \[including Gelatin and Jelly dessert\] and soup) was added to the total fluid intake. Samples were taken on Day 0 (baseline) at the corresponding Day 1 predose time and 12 hours postdose time; and on Day 1 at predose and at 2, 4, 6, 8, 12, and 24 hours postdose.

Time frame:
Baseline and Day 2
Reported as:
Mean · mL
Change From Baseline in Fluid Intake From 0-6 Hours, 0-12 Hours and 0-24 Hours
mLTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
Day 1 (0 to 6 hour)97.5 ± 461.9-255.0 ± 257.3-103.0 ± 693.2
Day 1 (0 to 12 hour)210.0 ± 558.1-65.0 ± 566.4118.8 ± 1019.6
Day 1 (0 to 24 hour)361.0 ± 647.0129.0 ± 632.1525.6 ± 1265.3
SecondaryChange From Baseline in Fluid Balance (Fluid Intake Minus Urine Output) From 0-6 Hours, 0-12 Hours and 0-24 Hours.

Fluid intake was monitored on Day 0 (times relative to Day 1 dosing), and Day 1 at intervals of 0 to 6, 6 to 12, and 12 to 24 hours postdose. Fluid intake included fluid used for dosing (study medication and any concomitant medication); food items that included any significant amounts of water (e.g., Jello \[including Gelatin and Jelly dessert\] and soup) was added to the total fluid intake. Urine was collected for baseline comparison on Day 0 for the 24 hour prior to Day 1 dosing at intervals of 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12 hours, and 12 to 24 hours relative to the Day 1 dosing time. Fluid balance was determined as fluid intake minus urine output.

Time frame:
2 days
Reported as:
Mean · mL
Change From Baseline in Fluid Balance (Fluid Intake Minus Urine Output) From 0-6 Hours, 0-12 Hours and 0-24 Hours.
mLTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
Day 1 (0 to 6 hour)-403.7 ± 783.2-856.8 ± 528.1-1478.8 ± 958.6
Day 1 (0 to 12 hour)-588.8 ± 1078.8-839.8 ± 553.7-1897.5 ± 1072.7
Day 1 (0 to 24 hour)-278.3 ± 1171.7-537.8 ± 831.1-1700.6 ± 1301.3
SecondaryChange From Baseline in Cumulative Urine Volume at 0-6 Hours, 0-12 Hours and 0-24 Hours.

Urine was collected for baseline comparison on Day 0 for the 24 hour prior to Day 1 dosing at intervals of 0 to 2, 2 to 4, 4, to 6, 6, to 8, 8, to 12, and 12 to 24 hours relative to Day 1 dosing time. Urine was collected on Day 1 at intervals of 0 to 2,2 to 4, 4 to 6, 6 to 8, 8 to 12, and 12 to 24 hours postdose. For the start of the urine collection on Day 0, a window of 15 to 40 minutes prior to the assigned dosing time was acceptable, with the 0 to 24 hour collection period on Day 1 starting 24 hours after the start time on Day 0. Participants were asked to void immediately prior to the end of the collection interval. The volume of individual voids were measured and recorded prior to refrigerating. All voids in a collection interval were pooled at the end of the collection interval, at which time the volume was determined, recorded and an aliquot taken for osmolality, sodium, potassium, and creatinine assessments.

Time frame:
2 days
Reported as:
Mean · mL
Change From Baseline in Cumulative Urine Volume at 0-6 Hours, 0-12 Hours and 0-24 Hours.
mLTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
Day 1 (0 to 6 hour)501.2 ± 584.4601.8 ± 486.61375.6 ± 911.6
Day 1 (0 to 12 hour)798.8 ± 1024.4774.8 ± 596.22016.3 ± 1668
Day 1 (0 to 24 hour)639.3 ± 1223.8666.8 ± 732.32226.3 ± 2151.5

Adverse events

Collected over Adverse events were reported from the signing of the informed consent throughout the study and were followed for 7 (+2) days post last dose of study medication.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan 3.75 mg—0/10 (0%)0/10 (0%)
Tolvaptan 7.5 mg—0/10 (0%)1/10 (10%)
Tolvaptan 15 mg—1/9 (11.1%)3/9 (33.3%)
Most frequent serious events
Most frequent serious events
EventTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
Small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/100/101/9
Most frequent other events
Most frequent other events
EventTolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mg
DizzinessNervous system disorders0/101/101/9
InsomniaPsychiatric disorders0/100/101/9
PolyuriaRenal and urinary disorders0/100/101/9

Baseline characteristics

The baseline analysis population comprised of all participants who had taken one dose of the study medication.

Age, Continuous
Age, Continuous(years)Tolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mgTotal
Mean68.50 ± 8.6670.20 ± 9.9059.67 ± 15.4366.34 ± 12.04
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan 3.75 mgTolvaptan 7.5 mgTolvaptan 15 mgTotal
Female68519
Male42410
08

Study locations

14 sites
  • Vseobecna fakultni nemocnice V Praze
    Praha, 128 08, Czech Republic
  • Holstebro Regionhospital
    Holstebro, 7500, Denmark
  • Medizinische Klinik im Klinikum Hannover
    Hannover, Niedersachsen 30167, Germany
  • Universitätsklinikum C.-G.-Carus
    Dresden, Sachsen 01307, Germany
  • Evangelische Lungenklinik Berlin
    Berlin, 13125, Germany
  • Universitaetsklinikum Koeln
    Koeln, 50937, Germany
  • Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
    Luebeck, 23538, Germany
  • Semmelweis Egyetem AOK
    Budapest, 1083, Hungary
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Clinico San Carlos
    Madrid, 28040, Spain
  • Sahlgrenska Universitetssjukhuset
    Göteborg, 41345, Sweden
  • Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • The Christie Hospital
    Manchester, M20 4BX, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2013
First posted
Dec 12, 2013
Start
Nov 2013
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
May 16, 2016
Last update
May 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02009878
Responsible party
Sponsor
First posted
Dec 12, 2013
Start date
Nov 2013
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
May 16, 2016
Last update
May 16, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion